Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352-5; PMID:18323444; http://dx.doi.org/10.1126/science.1140735
   PubMed Web of Science ®Google Scholar
• Chu G. Double strand break repair. J Biol Chem 1997; 272:24097-100; PMID:9305850; http://dx.doi.org/10.1074/jbc.272.39.24097
   PubMed Web of Science ®Google Scholar
• Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008; 18:134-47; PMID:18157161; http://dx.doi.org/10.1038/cr.2007.111
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204; PMID:18256616; http://dx.doi.org/10.1038/nrc2342
   PubMed Web of Science ®Google Scholar
• Mao Z, Jiang Y, Liu X, Seluanov A, Gorbunova V. DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia 2009; 11:683-91; PMID:19568413; http://dx.doi.org/10.1593/neo.09312
   PubMed Web of Science ®Google Scholar
• Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, Durkacz BW. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004; 103:4659-65; PMID:15010369; http://dx.doi.org/10.1182/blood-2003-07-2527
   PubMed Web of Science ®Google Scholar
• Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC, Curtin NJ. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006; 66:5354-62; PMID:16707462; http://dx.doi.org/10.1158/0008-5472.CAN-05-4275
   PubMed Web of Science ®Google Scholar
• Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M, Kumar S, Pandey M, Singh RK, Ray P, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 2012; 151:1474-87; PMID:23260137; http://dx.doi.org/10.1016/j.cell.2012.11.054
   PubMed Web of Science ®Google Scholar
• Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, Kozikowski AP, Connell PP. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem 2013; 56:254-63; PMID:23231413; http://dx.doi.org/10.1021/jm301565b
   PubMed Web of Science ®Google Scholar
• Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, Stark JM, Kozikowski AP, Bishop DK, Connell PP. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 2012; 40:7347-57
   PubMed Web of Science ®Google Scholar
• Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, Mazin AV. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol 2011; 6:628-35; PMID:21428443; http://dx.doi.org/10.1021/cb100428c
   PubMed Web of Science ®Google Scholar
• Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci 2014; 105:370-88; PMID:24484288; http://dx.doi.org/10.1111/cas.12366
   PubMed Web of Science ®Google Scholar
• Gockler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 2009; 276:6324-37; PMID:19796173; http://dx.doi.org/10.1111/j.1742-4658.2009.07346.x
   PubMed Web of Science ®Google Scholar
• Bergstrom M, Westerberg G, Langstrom B. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol 1997; 24:287-93; PMID:9257326; http://dx.doi.org/10.1016/S0969-8051(97)00013-9
   PubMed Web of Science ®Google Scholar
• Li Y, Sattler R, Yang EJ, Nunes A, Ayukawa Y, Akhtar S, Ji G, Zhang PW, Rothstein JD. Harmine, a natural β-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacol 2011; 60:1168-75; PMID:21034752; http://dx.doi.org/10.1016/j.neuropharm.2010.10.016
   PubMed Web of Science ®Google Scholar
• Song Y, Kesuma D, Wang J, Deng Y, Duan J, Wang JH, Qi RZ. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun 2004; 317:128-32; PMID:15047157; http://dx.doi.org/10.1016/j.bbrc.2004.03.019
   PubMed Web of Science ®Google Scholar
• Ma Y, Wink M. The β-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res 2010; 24:146-9; PMID:19548284; http://dx.doi.org/10.1002/ptr.2860
   PubMed Web of Science ®Google Scholar
• Zaker F, Oody A, Arjmand A. A study on the antitumoral and differentiation effects of peganum harmala derivatives in combination with ATRA on leukaemic cells. Arch Pharm Res 2007; 30:844-9; PMID:17703736; http://dx.doi.org/10.1007/BF02978835
   PubMed Web of Science ®Google Scholar
• Hamsa TP, Kuttan G. Harmine activates intrinsic and extrinsic pathways of apoptosis in B16F-10 melanoma. Chinese Med 2011; 6:11; PMID:21429205; http://dx.doi.org/10.1186/1749-8546-6-11
   PubMedGoogle Scholar
• Seluanov A, Mao Z, Gorbunova V. Analysis of DNA double-strand break (DSB) repair in mammalian cells. J Vis Exp 2010; 8(43). pii: 2002. doi: 10.3791/2002
   Google Scholar
• Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, Gorbunova V. DNA end joining becomes less efficient and more error-prone during cellular senescence. Proc Natl Acad Sci USA 2004; 101:7624-9
   PubMed Web of Science ®Google Scholar
• Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, Seluanov A, Gorbunova V. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011; 332:1443-6; PMID:21680843; http://dx.doi.org/10.1126/science.1202723
   PubMed Web of Science ®Google Scholar
• Mao Z, Seluanov A, Jiang Y, Gorbunova V. TRF2 is required for repair of nontelomeric DNA double-strand breaks by homologous recombination. Proc Natl Acad Sci USA 2007; 104:13068-73
   PubMed Web of Science ®Google Scholar
• Mao Z, Tian X, Van Meter M, Ke Z, Gorbunova V, Seluanov A. Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence. Proc Natl Acad Sci USA 2012; 109:11800-5
   Google Scholar
• Chen S, Wang C, Sun L, Wang DL, Chen L, Huang Z, Yang Q, Gao J, Yang XB, Chang JF, et al. RAD6 promotes homologous recombination repair by activating the autophagy-mediated degradation of heterochromatin protein HP1. Mol Cell Biol 2015; 35:406-16; PMID:25384975; http://dx.doi.org/10.1128/MCB.01044-14
   PubMed Web of Science ®Google Scholar
• Essers J, Houtsmuller AB, van Veelen L, Paulusma C, Nigg AL, Pastink A, Vermeulen W, Hoeijmakers JH, Kanaar R. Nuclear dynamics of RAD52 group homologous recombination proteins in response to DNA damage. EMBO J 2002; 21:2030-7; PMID:11953322; http://dx.doi.org/10.1093/emboj/21.8.2030
   PubMed Web of Science ®Google Scholar
• Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, West SC. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001; 7:273-82; PMID:11239456; http://dx.doi.org/10.1016/S1097-2765(01)00175-7
   PubMed Web of Science ®Google Scholar
• Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000; 14:1448-59; PMID:10859164; http://dx.doi.org/10.1101/gad.840500
   PubMed Web of Science ®Google Scholar
• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-8; PMID:19847258; http://dx.doi.org/10.1038/nature08467
   PubMed Web of Science ®Google Scholar
• Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-9; PMID:11100718; http://dx.doi.org/10.1038/35044005
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 2009; 361:123-34; PMID:19553641; http://dx.doi.org/10.1056/NEJMoa0900212
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376:245-51; PMID:20609468; http://dx.doi.org/10.1016/S0140-6736(10)60893-8
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-44; PMID:20609467; http://dx.doi.org/10.1016/S0140-6736(10)60892-6
   PubMed Web of Science ®Google Scholar
• Boeira JM, Viana AF, Picada JN, Henriques JA. Genotoxic and recombinogenic activities of the two β-carboline alkaloids harman and harmine in Saccharomyces cerevisiae. Mutat Res 2002; 500:39-48; PMID:11890933; http://dx.doi.org/10.1016/S0027-5107(01)00294-9
   PubMed Web of Science ®Google Scholar
• Boeira JM, da Silva J, Erdtmann B, Henriques JA. Genotoxic effects of the alkaloids harman and harmine assessed by comet assay and chromosome aberration test in mammalian cells in vitro. Pharmacol Toxicol 2001; 89:287-94; PMID:11903953; http://dx.doi.org/10.1034/j.1600-0773.2001.d01-162.x
   PubMedGoogle Scholar
• Ishida J, Wang HK, Bastow KF, Hu CQ, Lee KH. Antitumor agents 201. Cytotoxicity of harmine and β-carboline analogs. Bioorg Med Chem Lett 1999; 9:3319-24; PMID:10612592; http://dx.doi.org/10.1016/S0960-894X(99)00598-3
   PubMed Web of Science ®Google Scholar
• Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10:2438-51; PMID:8843196; http://dx.doi.org/10.1101/gad.10.19.2438
   PubMed Web of Science ®Google Scholar
• Ryan KM, Vousden KH. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998; 18:3692-8; PMID:9632751
   PubMed Web of Science ®Google Scholar
• Stahler F, Roemer K. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. Oncogene 1998; 17:3507-12; PMID:10030675; http://dx.doi.org/10.1038/sj.onc.1202245
   PubMed Web of Science ®Google Scholar